Prodrug of an ice inhibitor
AssigneeVertex Pharmaceuticals Incorporated
InventorsMarion W. WANNAMAKER, Robert J. DAVIES
Life of this patent
Estimating the term…
Abstract
This invention describes an ICE inhibitor prodrug (I) having good bioavailability. Compound I is useful for treating IL-1 mediated diseases such as rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, inflammatory peritonitis, septic shock, pancreatitis, traumatic brain injury, organ transplant rejection, osteoarthritis, asthma, psoriasis, Alzheimer's disease, myocardial infarction, congestive heart failure, Huntington's disease, atherosclerosis, atopic dermatitis, leukemias and related disorders, myelodysplastic syndrome, uveitis or multiple myeloma.
Claims25
-12. (canceled)
A topical formulation comprising an active ICE inhibitor II having a formula:
- or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.
A method of treating a disease in a subject in need thereof comprising the step of administering to said subject a pharmaceutical composition comprising an active ICE inhibitor II having a formula:
- or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle, wherein the disease is atopic dermatitis, psoriasis, acute dermatomyositis, eczema, or metastatic melanoma, or a combination thereof.
A method of treating atopic dermatitis in a subject in need thereof comprising the step of administering to said subject a pharmaceutical composition comprising an active ICE inhibitor II having a formula:
- or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, adjuvant, or vehicle.
Dependencies are inferred from the claim text.